ArticleBritish journal of cancer1998
Comparative genomic hybridization and telomerase activity analysis identify two biologically different groups of 4s neuroblastomas.
Article in British journal of cancer, 1998. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01728155 (European Low and Intermediate Risk Neuroblastoma Protocol), which is not on this map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
European Low and Intermediate Risk Neuroblastoma Protocol
Who cites it
16 citing papers in PubMed.
- Chromosome instability in neuroblastoma: A pathway to aggressive disease.Frontiers in oncology · 2022Review
- The Over-Expression of E2F3 Might Serve as Prognostic Marker for Neuroblastoma Patients with Stage 4S Disease.Diagnostics (Basel, Switzerland) · 2020Article
- Stage 4 s neuroblastoma: features, management and outcome of 268 cases from the Italian Neuroblastoma Registry.Italian journal of pediatrics · 2019Article
- G-quadruplexes as potential therapeutic targets for embryonal tumors.Molecules (Basel, Switzerland) · 2013Review
- Comparison of different techniques for the detection of genetic risk-identifying chromosomal gains and losses in neuroblastoma.Virchows Archiv : an international journal of pathology · 2008Article
- Chromosomal CGH identifies patients with a higher risk of relapse in neuroblastoma without MYCN amplification.British journal of cancer · 2007Article
- Chromosome 6p amplification and cancer progression.Journal of clinical pathology · 2007Review
- Prognostic value of the International Neuroblastoma Pathology Classification in Neuroblastoma (Schwannian stroma-poor) and comparison with other prognostic factors: a study of 182 cases from the Spanish Neuroblastoma Registry.Virchows Archiv : an international journal of pathology · 2006Article
- Telomerase detection in the diagnosis and prognosis of cancer.Cytotechnology · 2004Article
- The epidemiology of neonatal tumours. Report of an international working group.Pediatric surgery international · 2003Review
- Neuroblastoma tumour genetics: clinical and biological aspects.Journal of clinical pathology · 2001Review
- Neuroblastomas with chromosome 11q loss and single copy MYCN comprise a biologically distinct group of tumours with adverse prognosis.British journal of cancer · 2001Article
- Alternative lengthening of telomeres is associated with chromosomal instability in osteosarcomas.Oncogene · 2001Article
- Evaluation of Endocrine Neoplasms Using Fine Needle Aspiration Biopsy.Endocrine pathology · 2000Article
- Chromosomal localization of DNA amplifications in neuroblastoma tumors using cDNA microarray comparative genomic hybridization.Neoplasia (New York, N.Y.)Article
- High telomerase activity correlates with the stabilities of genome and DNA ploidy in renal cell carcinoma.Neoplasia (New York, N.Y.)Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chromosomal aberrations of 20 stage 4s neuroblastomas were analysed by comparative genomic hybridization (CGH). In a subset of 13/20 tumours, telomerase activity was evaluated by the telomeric repeat amplification protocol (TRAP). The CGH data were compared with the CGH results of ten stage 1 and 2 (stage 1/2) and 22 stage 3 and 4 (stage 3/4) neuroblastomas. A total of 17/20 stage 4s neuroblastomas did not progress clinically, whereas tumour progression with lethal outcome occurred in 3/20 cases. The CGH data of clinically non-progressing stage 4s tumours revealed a high rate of whole-chromosome aberrations (73.4%) with an overrepresentation of mainly chromosomes 2, 6, 7, 12, 13, 17, 18 and an underrepresentation of mainly chromosomes 3, 4, 11, 14. MYCN amplification or 1p deletion was observed in only 1/27 or 2/17 clinically non-progressing stage 4s tumours respectively, whereas all three progressive stage 4s neuroblastomas showed MYCN amplification, 1p deletion and, in 2/3 cases, distal 17q gains. Except for one case, telomerase activity was not observed in non-progressing stage 4s neuroblastomas. In contrast, 4s tumours with lethal outcome revealed elevated telomerase activity levels. Our data suggest that stage 4s neuroblastomas belong to two biologically different groups, one of which displays the genetic features of localized stage 1/2 tumours, whereas the other mimics advanced stage 3/4 neuroblastomas.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.